Two NIH Institutes Will Fund New Synchrotron Beamlines

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Cristiane Decat Bergerot, PhD

April 14th 2025

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.

Russ Conroy

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.

Related Content

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Tim Cortese

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Cristiane Decat Bergerot, PhD

April 14th 2025

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Russ Conroy